InMed-logo-01
Subscribe
NASDAQ_Logo

Press Releases

Press Releases

InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update
InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021
InMed Pharmaceuticals and BayMedica Participating in Tribe Public’s Webinar "Accelerating The Commercialization of Rare Cannabinoids"
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th
InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference
InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules
Displaying 1 - 10 of 185
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Manufacturing

Pharmaceutical

Investor

Products

About

Learn

© Copyright 2021 InMed Pharmaceuticals Inc.